One of the primary services of the MedInvest Scanner is the provision of competitive emerging technology reports, so called CTRs. As a result of a landscape investigation, we can inform you not only of technologies already on the market but also of those which are beyond the horizon.
A Competitive Emerging Technology Report embraces information which can be gathered at a given time in order to further decrease your investment risk. There is no better source. Through utilizing the CTR, it is possible to reduce investment risk to the level of only 5 to 10%.
First we conduct horizon scanning and perform critical appraisal of available scientific evidence. The CTR contains information concerning the competitive environment and alternative market access strategies of upcoming products. Within the analyses, we assess the innovativeness of a given medical product along with its added-value compared to current and prospective treatment or diagnostic options.
Most of all, within CTR, MedInvest Scanner will provide you with information on expected prices of technologies entering the market in the 2 to 3 upcoming years, due to Value Based Pricing criteria. CTR also embraces evaluation of budget impact in a given market segment in selected countries. It takes about 3 months to develop full CTR.
If time is limited but also as a preliminary analysis one can be interested in a rapid CTR. Rapid CTR (rCTR) embraces simplified analysis similar to full CTR. It provides quick insight to a landscape but with higher uncertainty around estimates due to time constrains. rCTR is usually delivered in one month.
Here examples of CTR and rCTR can be downloaded:
Rapid CTR Illumina MiSeqDx
CTR HeartFlow - short